193. プラダー・ウィリ症候群 Prader-Willi syndrome Clinical trials / Disease details


臨床試験数 : 111 薬物数 : 122 - (DrugBank : 30) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 103

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03649477
(ClinicalTrials.gov)
November 20, 201824/8/2018Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi SyndromePhase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)Prader-Willi SyndromeDrug: 3.2 mg intranasal carbetocin;Drug: 9.6 mg intranasal carbetocin;Drug: placeboLevo Therapeutics, Inc.NULLActive, not recruiting7 Years18 YearsAll130Phase 3United States;Australia;Canada